INNOVATION THAT GOES BEYOND HEALING
About Us
Life After Well
At Qcil, we believe that health isn't merely the absence of illness, but the vibrant pursuit of life's possibilities. In Africa, vitality and resilience are virtues we celebrate – which is why for us, it's not about surviving, it's about thriving. This is what makes us more than just medication manufacturers. We embody the spirit of living vigorously – at the heart of our commitment to scientific innovation and true wellness, captured in our mantra, "Life After Well”.
Vision
To become a centre of excellence in the manufacturing of quality, affordable medicines.
Mission
To provide affordable and efficacious medicines in a sustainable way, to improve the quality of life.
Standards
The plant has been designed to meet the world's most stringent regulatory standards.
Governance
In September 2018, following a successful Initial Public Offering, Qcil shares were listed on the Uganda Securities Exchange.
Values
Quality
Excellence
Accountability
Teamwork
Integrity
Customer Focus
Innovation
Who Are We
Made in Africa, for Africa
Qcil is committed to making the highest quality, affordable, lifesaving medicines, because we want people to live long and healthy lives. We see a future where good health is expected – not for the few, but for the many. That's why we believe no one should be denied access to essential medicines. We're not just about making medicine, we're about making a difference.
Growth Opportunities
Qcil continually strives to produce quality, affordable medicines, that will meet the demands of the increasing African population. In addition to producing medicine to treat malaria, HIV and Hepatitis B, Qcil is exploring the production of medicine to manage the surge of cardiovascular diseases and anti-diabetic, anti-tuberculosis and pain management medicines.
Corporate Culture
Qcil employs more than 350 permanent staff, of which 38% are female. We are an equal opportunity employer and do not discriminate on gender, age, disability, ethnicity, religious grounds, or nationality. We take immense pride in empowering our staff through training and development initiatives which, in turn, enhances their ability to deliver the best results for the business.
Our Leadership
Board of Directors
Management Team
Milestones & Awards
Winner
Federation of Uganda Employer Award for Disability Inclusion 2023
Winner
Outstanding Performance In Occupational Safety & Health Management For The Year 2023
Winner
Best Practices In Learning And Development - 2022 Survey
Winner
Employer Of The Year Award - 2021/22 Survey
Winner
Best Reward and Recognition Award - Prudential Best HR Practice Survey 2021
Winner
Financial Reporting Award - Fire Awards 2021
Winner
Indian Business Forum Award (Contribution towards the Pharmaceutical/Health sector: 2018)
Winner
Africa Award for Entrepreneurship (Transformational Business of the Year: 2012)
Winner
Outstanding Achievement In Development Of The Pharmaceutical Sector (Ministry of Health: 2012)
Winner
Investor Of The Year (Uganda Investment Authority: 2007)
Manufacturing Excellence
WHO-compliant Facilities
Qcil aims to produce pharmaceutical products of the highest quality, that adhere strictly to cGMP and GLP, and numerous other international regulatory standards.
Qcil is one of the largest pharmaceutical manufacturers in East Africa and also one of the largest in SSA. Qcil is one of the few pharmaceutical manufacturers to operate a WHO cGMP-compliant facility, which manufactures a range of WHO pre-qualified medicines for treating HIV/AIDS and malaria.
ISO Certified
Qcil has obtained ISO certifications for Environmental Management Systems (SO 14001:2015) and Occupational Health and Safety Management Systems (ISO 45001:2018). This helps Qcil promote better environmental management systems. We take pride in holding ourselves accountable against international best practice.
Factory Tour
Qcil has focused on aggressive market expansion over the past few years. As a result, the company has obtained approval from national regulatory bodies across numerous African countries. Qcil is listed for approval in South Africa, the single biggest market for antiretrovirals in the world.
The facility is approved for supply in 31 SSA countries and currently exports to 13 countries in Africa and 2 in South East Asia. Qcil's manufacturing facility has also been expanded, increasing production capacity from 80 million to 130 million tablets monthly, to meet demand.
In December 2019, Qcil commissioned a $10 million state-of-the-art quality control laboratory, which is double the size of the previous laboratory, accommodating more staff and ensuring that the company is compliant with all safety and good laboratory practice requirements.
The new facility has also helped to increase productivity and improve production timelines.
Qcil constructed a new $5 million warehouse, with 3000 sqm, to increase in-house storage capacity and discontinue the use of third-party warehouses. The warehouse has been operational since January 2019 and has capacity for 5000 pallets.
